Compare NTB & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NTB | GPCR |
|---|---|---|
| Founded | 1858 | 2016 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.8B |
| IPO Year | 2016 | 2023 |
| Metric | NTB | GPCR |
|---|---|---|
| Price | $60.20 | $47.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $53.75 | ★ $103.17 |
| AVG Volume (30 Days) | 127.5K | ★ 650.3K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.84 | N/A |
| Revenue Next Year | $4.16 | N/A |
| P/E Ratio | $9.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.59 | $15.80 |
| 52 Week High | $62.46 | $94.90 |
| Indicator | NTB | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 51.69 | 46.12 |
| Support Level | $57.71 | $43.76 |
| Resistance Level | $61.11 | $57.15 |
| Average True Range (ATR) | 1.03 | 2.59 |
| MACD | -0.18 | -0.67 |
| Stochastic Oscillator | 33.13 | 24.95 |
Bank of N.T Butterfield & Son Ltd is a full-service bank and wealth manager. It offers banking services, comprising retail and corporate banking, and wealth management services, which consist of trust, private banking, and asset management business. The company operates through four reportable segments: Bermuda, Cayman, Channel Islands and the UK, and Other. In its Bermuda and Cayman segments, the company offers retail banking and wealth management services. In the Channel Islands and the UK segment, the company offers retail and corporate banking and wealth management services, and the Other segment includes its operations in the Bahamas, Canada, Mauritius, Singapore, and Switzerland. Maximum revenue for the company is generated from its business in Bermuda.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.